Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Moclobemide and placebo in mild major depression: a double-blind randomized trial

  • 35 Accesses

  • 14 Citations

Abstract

Sixty-eight patients participated in this double-blind randomised study with moclobemide versus placebo (35 allocated to moclobemide; 33 to placebo). In terms of mean HAMD total scores, improvement tended to be more pronounced in the moclobemide group at treatment end-point. Efficacy was judged to be ‘very good’ or ‘good’ in 50% of moclobemide-treated patients and in 27% of placebo-treated patients: in completers only, the difference was more marked (69% versus 33%;P<0.05 Mann-Whitney test). Tolerability was judged to be ‘very good’ or ‘good’ in 77% of moclobemide-treated patients and in 94% of placebo-treated patients. Adverse events were observed in 31% of patients in the moclobemide group and in 18% of patients in the placebo group.

This is a preview of subscription content, log in to check access.

Author information

Correspondence to E. Ose.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ose, E., Holm, P. Moclobemide and placebo in mild major depression: a double-blind randomized trial. Psychopharmacology 106, S114–S115 (1992). https://doi.org/10.1007/BF02246251

Download citation

Key words

  • Moclobemide
  • Depression